Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥﹕治療突變肺癌藥監管註冊申請於歐洲和日本獲受理

Future Wealths
Future Wealths
2 11 月, 2026
One Min Read
2 Views
0 Comments
和黃醫藥(0013)公布，沃瑞沙®（賽沃替尼/ savolitinib）和泰瑞沙®​（奧希替尼/ osimertinib）聯合療法在歐洲和日本的監管註冊申請已獲受理。

原文: https://finance.mingpao.com/fin/instantf/20261102/1793578865569/%E5%92%8C%E9%BB%83%E9%86%AB%E8%97%A5-%E6%B2%BB%E7%99%82%E7%AA%81%E8%AE%8A%E8%82%BA%E7%99%8C%E8%97%A5%E7%9B%A3%E7%AE%A1%E8%A8%BB%E5%86%8A%E7%94%B3%E8%AB%8B%E6%96%BC%E6%AD%90%E6%B4%B2%E5%92%8C%E6%97%A5%E6%9C%AC%E7%8D%B2%E5%8F%97%E7%90%86%22%20target=%22blank

Last Update: 2 11 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept